• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Incyte Corp. filed SEC Form 8-K: Leadership Update

    6/27/25 4:54:02 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email
    false 0000879169 0000879169 2025-06-23 2025-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 23, 2025

     

    INCYTE CORPORATION 

    (Exact name of registrant as specified in its charter)

     

    Delaware
    (State or Other Jurisdiction of
    Incorporation)
      001-12400
    (Commission File Number)
      94-3136539
    (I.R.S. Employer
    Identification No.)

     

    1801 Augustine Cut-Off    
    Wilmington, DE   19803
    (Address of principal executive offices)   (Zip Code)

     

    (302) 498-6700

    (Registrant’s telephone number,
    including area code)

     

    N/A

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $.001 par value per share   INCY   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

     

    Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Retirement of President and Chief Executive Officer

     

    On June 26, 2025, Incyte Corporation (the “Company”) announced that Hervé Hoppenot retired as President and Chief Executive Officer of the Company effective June 26, 2025. Mr. Hoppenot will continue to serve as a member of the Company’s Board of Directors (the “Board”). Julian C. Baker, Lead Independent Director of the Board, assumed the role of Chairman of the Board effective June 26, 2025.

     

    In connection with his retirement, the Company and Mr. Hoppenot entered into a transition agreement (the “Transition Agreement”), dated as of June 26, 2025 (the “Effective Date”), pursuant to which Mr. Hoppenot will serve as special advisor to the Company’s Chief Executive Officer and will provide advice and counsel in connection with the Chief Executive Officer transition as may be reasonably requested by the Chief Executive Officer or the Board. The term of Mr. Hoppenot’s employment will continue until the first anniversary of the Effective Date or such earlier date as either the Company or Mr. Hoppenot may determine (the “Transition Completion Date”). For a one year period following the Transition Completion Date, Mr. Hoppenot will serve as a non-employee consultant to assist the Company in transitional matters. Pursuant to the Transition Agreement, the Company will compensate Mr. Hoppenot for his services for the first six months commencing on the Effective Date at his current annual base salary rate of $1,395,731 (the “Annual Base Salary Rate”) and for the following six months at 50% of the Annual Base Salary Rate. In addition, the Company will pay Mr. Hoppenot a prorated portion of the bonus to which he would have been entitled under the Company’s 2025 Incentive Compensation Plan. Mr. Hoppenot will also receive (i) time-based restricted stock units (“RSUs”) for 6,016 shares of the Company’s common stock (“Common Stock”), which will vest as to 25% of the shares subject to the RSUs on each of the first four anniversaries of the grant date, (ii) options to purchase 18,438 shares of Common Stock, which will vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal monthly installments over the subsequent 36 months, and (iii) performance shares with a target number of shares of Common Stock of 18,050, which cliff vest on the third anniversary of the grant date. The performance shares will be subject to the same performance goals as those to be issued to the Company’s executive officers in connection with the Company’s 2025 annual equity award grants, and can be earned at 0-200% of target based on the Company’s relative total share return (“TSR”) performance over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in the same fixed peer group that will be used for the Company’s 2025 annual performance share awards to its executive officers. The Transition Agreement further provides that, in addition to Mr. Hoppenot’s equity awards that were granted after July 15, 2019 through December 31, 2024 that were covered by his employment agreement with the Company, his equity awards granted after January 1, 2025 and through and including the Effective Date (including the awards described in this paragraph) will continue to vest, become exercisable and payable after the Transition Completion Date at the same times and under the same conditions as if Mr. Hoppenot continued to be employed by the Company following the Transition Completion Date provided that Mr. Hoppenot’s continues to comply with certain covenants contained in the Transition Agreement. The Transition Agreement also confirms that upon a Change in Control (as defined in the Transition Agreement), Mr. Hoppenot will continue be entitled to receive the compensation and benefits set forth in the Transition Agreement.

     

    The foregoing description of the Transition Agreement is only a summary and is qualified in its entirety by the terms of the Transition Agreement, a copy of which is filed herewith as Exhibit 10.1.

     

    Appointment of President and Chief Executive Officer

     

    On June 26, 2025, the Company announced that it has appointed William J. Meury as President and Chief Executive Officer, effective June 26, 2025.  Mr. Meury has also been appointed to the Board effective June 26, 2025.

     

    2

     

     

    Biographical Information. Mr. Meury, age 57, served as President and Chief Executive Officer of Anthos Therapeutics, Inc., a privately-held biopharmaceutical company, from April 2024 until its acquisition by Novartis in April 2025. From January 2023 through March 2024, Mr. Meury served as President and Chief Executive Officer of Karuna Therapeutics, Inc., a publicly traded biopharmaceutical company that was acquired by Bristol-Myers Squibb Company. From May 2020 through December 2022, Mr. Meury served as a Partner at Hildred Capital Management, a private equity firm focusing on the healthcare industry. Prior to joining Hildred Capital Management, Mr. Meury served as the Chief Commercial Officer of Allergan plc, a global pharmaceutical company, from May 2016 through its acquisition by AbbVie Inc. in May 2020. Mr. Meury previously served as Allergan’s President, Branded Pharma from March 2015 to May 2016 and joined Allergan in July 2014 as Executive Vice President, Commercial, North American Brands. He has significant experience in launching and commercializing healthcare products. Prior to joining Allergan, Mr. Meury served as Executive Vice President, Sales and Marketing at Forest Laboratories, Inc., a specialty pharmaceutical company that was acquired by Actavis plc in July 2014. He joined Forest in 1993 and held multiple roles of increasing responsibility in marketing, new products, business development, and sales. Before joining Forest, Mr. Meury worked in public accounting for Reznick, Fedder & Silverman and in financial reporting for MCI Communications, Inc. Mr. Meury earned his B.A. in Economics from the University of Maryland.

     

    Compensation Arrangements. In connection with his appointment as President and Chief Executive Officer, Mr. Meury and the Company entered into an offer of employment letter (the “Offer Letter”) dated as of June 23, 2025 and an Employment Agreement (the “Employment Agreement”) dated as of June 26, 2025.

     

    Pursuant to the Offer Letter, upon commencement of employment Mr. Meury is entitled to an initial annual base salary of $1,250,000 and will participate in the Company’s annual Incentive Compensation Plan with a funding target for a cash bonus under such Plan of 100% of his annual base salary, and with such bonus to be pro-rated for 2025.  Beginning in 2026, Mr. Meury’s base salary will be reviewed annually by the Compensation Committee of the Board. Future bonuses under the annual Incentive Compensation Plan will be determined by the Compensation Committee in its discretion based on the achievement of performance goals to be determined annually by the Board. In addition, the Offer Letter provides for grants to Mr. Meury of the following equity awards: (i) a regular annual equity award of time-based RSUs for 36,101 shares of Common Stock, which will vest as to 25% of the shares subject to the RSUs on each of the first four anniversaries of the grant date (the “Sign-on RSU Award”), (ii) a regular annual equity award of options to purchase 110,630 shares of Common Stock, which will vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal monthly installments over the subsequent 36 months, (iii) a regular annual equity award of performance shares for a target number of shares of Common Stock of 108,303, which cliff vest on the third anniversary of the grant date, will be subject to the same terms as those to be issued to the Company’s other executive officers in mid-July 2025 in connection with the Company’s annual equity award grants, and can be earned at 0-200% of target based on the Company’s relative TSR performance over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in the same fixed peer group that will be used for the Company’s July 2025 annual performance share awards to its other executive officers, and (iv) a one-time sign-on award of performance shares for a target number of 125,000 shares of Common Stock, which can be earned at 0-400% of target based on actual stock price performance and which are subject to service and performance vesting conditions, with service vesting on the later of the first anniversary of the grant date and the achievement of the applicable stock price hurdle, and performance vesting conditions that can be earned on achievement of significant sustained stock price appreciation hurdles over a six-year period (and which settle on an extended basis via the issuance of Common Stock after the vesting of the performance shares and between the third and sixth anniversaries of the hiring date, as applicable) (the “Sign-On PSU Award”). Mr. Meury will also receive certain relocation and commuting benefits.

     

    The Employment Agreement provides for certain payments and benefits in the event of termination of Meury’s employment with the Company as follows (capitalized terms not defined in this Report have the meanings ascribed to them in the Employment Agreement, a copy of which has been filed as Exhibit 10.3 to this Report):

     

    If Mr. Meury voluntarily terminates his employment with the Company other than for Good Reason and other than in the 24-month period following a Change in Control (the “Change in Control Employment Period”), the Company will pay Mr. Meury, to the extent not already paid, his annual base salary through the date of termination, any deferred compensation and any accrued vacation pay.

     

    If Mr. Meury voluntarily terminates his employment with the Company without Change in Control Good Reason in the Change in Control Employment Period, the Company will pay Mr. Meury, to the extent not already paid, his annual base salary through the date of termination, any deferred compensation, any accrued vacation pay, and an amount equal to a pro rata portion of his target bonus calculated according to the number of days he worked through the date of termination in the current fiscal year.

     

    3

     

     

    If, at any time other than during the Change in Control Employment Period, Mr. Meury’s employment is terminated by the Company without Cause or by Mr. Meury for Good Reason, the Company will pay Mr. Meury, to the extent not already paid, his annual base salary through the date of termination, any deferred compensation, any accrued vacation pay, and an amount equal to a pro rata portion of his bonus based on actual performance and calculated according to the number of days he worked through the date of termination in the current fiscal year. In addition, the Company will pay him an amount equal to 1.5 times the sum of his annual base salary and his current target bonus. The Employment Agreement also provides that Mr. Meury’s options and Sign-On RSU Award will vest as to the amount that would have vested had he continued to work for the Company for an additional 18 months, and the Sign-On PSU award will remain outstanding and eligible to achieve any of the applicable performance goals for 120 days following such termination. All options would continue to be exercisable for 180 days following the date of termination. The Employment Agreement also provides for the payment of COBRA premiums by the Company, or the cash equivalent thereof, for Mr. Meury and his family for up to 18 months, outplacement services for up 12 months, as well as payment with respect to any other accrued amounts under other of the Company’s benefits arrangements.

     

    If during the Change in Control Employment Period Mr. Meury’s employment is terminated by the Company without Cause or by Mr. Meury for Change in Control Good Reason, the Company will pay Mr. Meury, to the extent not already paid, his annual base salary through the date of termination, any deferred compensation, any accrued vacation pay, and an amount equal to a pro rata portion of his target bonus calculated according to the number of days he worked through the date of termination in the current fiscal year. In addition, the Company will pay Mr. Meury an amount equal to two times the sum of his current annual base salary and his current target bonus. The Employment Agreement also provides that in the event of such a termination, all of Mr. Meury’s unvested RSUs and unvested stock options will vest in full, and all stock options will remain exercisable for 12 months following his termination. In addition, all performance shares (including the Sign-On PSUs) will be treated in accordance with their respective award agreements.  The Employment Agreement also provides for the continuation of benefits for Mr. Meury and his family for up to 24 months, outplacement services for up 12 months, as well as payment with respect to any other accrued amounts under other of the Company’s benefits arrangements.

     

    If Mr. Meury retires on a date after December 31, 2035 (as such date may be extended by mutual agreement), all outstanding equity awards that are granted by the Company to Mr. Meury after July 15, 2030 and before December 31, 2035 (or such later date after December 31, 2035 as may be mutually agreed upon) would continue to vest as if he continued to be employed by the Company following the date of his retirement. In addition, any outstanding stock option awards that are granted to Mr. Meury after July 15, 2030 and before December 31, 2035 (or such later date after December 31, 2035 as may be mutually agreed upon) that either were vested at the date of his retirement or become vested due to the post-retirement continued vesting provisions will be exercisable during the remainder of their original term. The effectiveness of these provisions will be subject to Mr. Meury’s continued compliance with the non-solicitation/non-hiring and non-disparagement covenants described below, including during any period of post-retirement continued vesting provided by the Employment Agreement.

     

    Under the Employment Agreement, Mr. Meury is subject to non-solicitation/non-hiring and non-disparagement covenants that extend two years from termination of employment. Upon certain breaches of those covenants after termination of employment, Mr. Meury must forfeit all of his unvested stock options, stock appreciation rights, RSUs, performance shares (including the Sign-On PSUs) and the gain or income realized from the exercise, vesting or settlement of the same within 24 months prior to the breach.

     

    The Company and Mr. Meury also entered into an Indemnity Agreement, the form of which has been filed as Exhibit 10.15 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

     

    The foregoing description of the Offer Letter and Employment Agreement with Mr. Meury is only a summary and is qualified in its entirety by the terms of the Offer Letter and the Employment Agreement, copies of which are filed herewith as Exhibit 10.2 and Exhibit 10.3, respectively.

     

    There is no family relationship between Mr. Meury and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company.

     

    4

     

     

    Amendment of 2024 Inducement Stock Incentive Plan

     

    Prior to the effectiveness of the grants of equity awards to Mr. Meury in accordance with the Offer Letter, the Board amended the Company’s 2024 Inducement Stock Incentive Plan (the “Inducement Plan”) to increase the number of shares authorized for issuance under the Inducement Plan from 1,000,000 to 2,000,000 and to remove the provision that states that any shares issued in connection with awards other than options and stock appreciation rights shall be counted against this authorized share limitation as 2.0 shares for every one share so issued..

     

    The foregoing description of the amendment to the Inducement Plan is qualified in its entirety by reference to the Inducement Plan, as amended, a copy of which is filed herewith as Exhibit 10.4.

     

    Item  9.01Financial Statements and Exhibits.

     

    (d)Exhibits

     

    10.1Transition Agreement between the Company and Hervé Hoppenot dated as of June 26, 2025,

     

    10.2Offer of Employment Letter, dated June 23, 2025, from the Company to William J. Meury.*

     

    10.3Employment Agreement between the Company and William J. Meury dated as of June 26, 2025.

     

    10.4Incyte Corporation 2024 Inducement Stock Incentive Plan, as amended on June 25, 2025.

     

    104Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

      *Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

     

    5

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 27, 2025

     

      INCYTE CORPORATION
         
      By: /s/ Sheila A Denton
        Sheila A. Denton
        Executive Vice President and
        General Counsel

     

    6

     

    Get the next $INCY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    9/18/2024$83.00 → $74.00Buy → Hold
    Truist
    7/2/2024$52.00 → $48.00Market Perform → Underperform
    BMO Capital Markets
    More analyst ratings

    $INCY
    SEC Filings

    See more
    • SEC Form 144 filed by Incyte Corp.

      144 - INCYTE CORP (0000879169) (Subject)

      7/3/25 2:46:56 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 filed by Incyte Corp.

      S-8 - INCYTE CORP (0000879169) (Filer)

      7/2/25 4:00:42 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Corp. filed SEC Form 8-K: Leadership Update

      8-K - INCYTE CORP (0000879169) (Filer)

      6/27/25 4:54:02 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Incyte Corporation (NASDAQ:INCY) announced today equity inducement awards grants to Bill Meury in connection with his appointment as the Company's new President and Chief Executive Officer. The awards are made pursuant to the Company's 2024 Inducement Stock Incentive Plan and were approved by the compensation committee of the Company's Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). As an inducement material to his employment and in lieu of the annual equity awards the Company typically grants in July of each year, Mr. Meury received, with a grant and vesting commencement date of

      7/2/25 4:30:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

      - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

      6/26/25 7:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

      Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura®), a topical Janus kinase (JAK) inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls (CMC) data on the 0.75% strength submitted by Incyte in response to a recent FDA information request. "Atopic dermatitis (AD) is a chronic

      6/20/25 4:30:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Incyte upgraded by Stifel with a new price target

      Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00

      6/16/25 7:42:04 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by Guggenheim

      Guggenheim downgraded Incyte from Buy to Neutral

      3/18/25 7:52:49 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by William Blair

      William Blair downgraded Incyte from Outperform to Mkt Perform

      3/18/25 7:52:29 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

      9/28/21 5:20:01 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

      9/23/21 5:11:12 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for OPZELURA issued to INCYTE CORP

      Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      9/22/21 11:16:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Human Resources Swain Paula J covered exercise/tax liability with 6,285 shares, decreasing direct ownership by 6% to 101,059 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:56:19 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Principal Accounting Officer Tray Thomas covered exercise/tax liability with 897 shares, decreasing direct ownership by 4% to 21,106 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:48:58 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP & Chief Medical Officer Stein Steven H covered exercise/tax liability with 12,714 shares, decreasing direct ownership by 10% to 112,418 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:48:25 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Incyte Corp.

      SC 13G - INCYTE CORP (0000879169) (Subject)

      10/17/24 9:39:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Incyte Corp.

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      6/14/24 6:23:05 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      5/13/24 6:06:33 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Financials

    Live finance-specific insights

    See more
    • Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

      Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

      6/15/25 3:15:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

      Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET) Incyte to host an in-person analyst and investor event highlighting the mutCALR data at EHA on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 - 1:30 p.m. CEST) Incyte (NASDAQ:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 20

      6/3/25 10:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

      – Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million – Opzelura® (ruxolitinib) cream net product revenues of $119 million in Q1'25 (+38% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $14 million in the first two months of U.S. launch demonstrating strong commercial execution and high patient need – New, 18-week data from ongoing Phase 3 study of povorcitinib in hidradenitis suppurativa (HS) demonstrates

      4/29/25 7:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

      - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

      6/26/25 7:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

      Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr

      6/12/23 4:01:00 PM ET
      $GLPG
      $INCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Incyte Names New Member to Its Board of Directors

      Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company

      10/4/22 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care